← Eichor
Study identifier: NCT04785443 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

Condition: Thyroid Diseases  ·  Sponsor: University Hospital, Brest

PhasePhase 3
Planned participants242
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

* Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months. * Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life. * The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism. * This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.

This description comes directly from the study's public registry record.

Talk to the study team

Jean-Christophe LECLERE, PhD  ·  0298223630  ·  jean-christophe.leclere@chu-brest.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHRU de BrestBrest, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04785443